TYR Expression serves as an inclusion eligibility criterion in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain TYR Expression as an inclusion criterion, 3 are phase 1 (3 open).
Trials with TYR Expression in the inclusion eligibility criteria most commonly target melanoma .
Til 1383i t-cell receptor-transduced autologous t-cells and bnt111 are the most frequent therapies in trials with TYR Expression as an inclusion criteria .
Significance of TYR Expression in Diseases
TYR Expression is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain TYR Expression and melanoma as inclusion criteria, 3 are phase 1 (3 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.